Semustine

Chronic Interstitial Nephropathy — representative incidence ~26%.

Dose-dependent and often severe. In a prospective adjuvant-melanoma cohort, renal dysfunction (including 3 cases of renal failure) occurred in 7/45 adults (16%) overall but 26% among those receiving >1,400 mg/m2 cumulative, with no injury seen below 1,400 mg/m2 (Micetich 1981). An NCI-assembled series of 35 cases found a high risk of severe nephrotoxicity once cumulative dose exceeded ~1,200 mg/m2, with children more susceptible than adults. A related nitrosourea (BCNU/methyl-CCNU) brain-tumor series reported impaired renal function in 17/18 patients who received >=6 courses (Schacht 1981), underscoring how steeply risk climbs with cumulative exposure.

Source: 16% overall and 26% above 1,400 mg/m2 cumulative in an adjuvant-melanoma cohort (Micetich 1981, PMID 7032289); high risk once cumulative dose exceeded ~1,200 mg/m2 across an NCI 35-case series (Weiss 1983, PMID 6360348).

Reported injury signatures: Chronic Interstitial Nephropathy, Glomerular Injury / Proteinuria.

1. Chronic Interstitial NephropathyPrimary
2. Glomerular Injury / ProteinuriaSecondary

Delayed (>6 weeks / cumulative) — Delayed and cumulative: injury may declare during treatment or only after completion — patients developed abnormal creatinine 1 month to 2 years after the last dose, worsening months to years later.

• High cumulative dose, risk rises steeply above ~1,200 mg/m2 (and clinically evident >1,400 mg/m2 in adults)
• Prolonged or repeated courses (many 8-week cycles)
• Pediatric age (children more susceptible than adults)
• Concurrent or prior nephrotoxins (cisplatin, other nitrosoureas, radiation to kidney fields)
• Pre-existing chronic kidney disease or reduced nephron mass

• Cap and track the lifetime cumulative dose, aggregating exposure across all nitrosoureas (BCNU/CCNU/streptozocin), and keep it well below the ~1,200 mg/m2 threshold
• Serial creatinine/eGFR before each cycle with discontinuation at the first sustained rise, remembering normal values during therapy do not guarantee safety
• Avoid stacking with other nephrotoxins and with nephrotoxic radiation fields
• Continue renal surveillance for years after the last dose, since injury can surface late

• Serum creatinine/eGFR and BUN before every cycle and periodically for years after the last dose
• Running tally of cumulative semustine dose (and total lifetime nitrosourea exposure)
• Urinalysis and quantified proteinuria, recognizing that a bland sediment does not exclude progressive injury
• Blood pressure and, in advanced disease, CKD labs (potassium, bicarbonate, phosphate, hemoglobin)

• Adjuvant malignant-melanoma trial cohort (Micetich 1981, Am J Med): prospective renal follow-up of 45 patients that defined the ~1,400 mg/m2 adult threshold and the late-onset pattern
• NCI pooled analysis of 35 semustine-nephrotoxicity cases (Weiss 1983, Cancer Treat Rep): established the cumulative-dose relationship (>1,200 mg/m2) and delayed, progressive course
• Nitrosourea brain-tumor series (Schacht 1981, Cancer): documented tubular atrophy, interstitial fibrosis, and glomerulosclerosis with rising incidence across BCNU/methyl-CCNU courses

• Cumulative-dose disease: nephrotoxicity tracks total exposure, not any single dose, risk climbs sharply beyond ~1,200 mg/m2 and is clinically overt above ~1,400 mg/m2 in adults.
• Late and relentless: creatinine can be normal throughout treatment and then rise months to 2 years after the last dose, and CKD may progress even after the drug is stopped.
• A silent urinalysis is the trap, a bland sediment with little proteinuria and no acute-renal-failure phase masks an insidious interstitial-fibrosing lesion; normal chemistries during therapy are falsely reassuring.
• Children are more susceptible than adults, so pediatric survivors warrant prolonged renal surveillance.
• Aggregate the exposure: count semustine toward a lifetime nitrosourea budget alongside carmustine, lomustine, and streptozocin, which share the class scarring effect.
• No rescue exists, capping cumulative dose and stopping early are the only effective interventions; glutathione biology (BSO worsens injury) explains why reactive-intermediate detox matters but has not translated to a clinical protectant.

• ADQI (2026) — Conventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupCisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.Kidney Int · PMID 41881107
• ADQI (2026) — The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupProvides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.Nat Rev Nephrol · PMID 41361704
• SIRM (2022) — SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.Radiol Med · PMID 35303246
• KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerIdentifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.Kidney Int · PMID 33126977
• KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationAddresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Kidney Int · PMID 33276867
• ADDIKD (2025) — Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceProvides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.EClinicalMedicine · PMID 40290844
• ADDIKD (2025) — Aligning kidney function assessment in patients with cancer to global practices in internal medicineThree consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.EClinicalMedicine · PMID 40290845
• ADDIKD (2025) — A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEstablishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.EClinicalMedicine · PMID 40290846
• KDIGO (2013) — Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.Crit Care · PMID 23394211
• KDIGO (2021) — Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesProvides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.Kidney Int · PMID 34556300
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisUpdates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.Kidney Int · PMID 38388147
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisUpdates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.Kidney Int · PMID 38182299
• KDIGO (2025) — Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.Kidney Int · PMID 40975525